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Introduction: A germline BIM deletion polymorphism has been 
proposed to predict poor treatment response to certain kinase inhibi-
tors. The purpose of this study was to explore whether the BIM dele-
tion polymorphism predicts treatment efficacy of epidermal growth 
factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in Korean 
patients with EGFR-mutant non–small-cell lung cancer (NSCLC).
Methods: Peripheral blood samples from a total of 205 patients with 
EGFR-mutant NSCLC who were treated with EGFR TKIs between 
July 2008 and April 2013 were included. The incidence of BIM dele-
tions in these samples was detected by polymerase chain reaction. We 
compared the clinical outcomes in patients with and without the poly-
morphism after treatment with EGFR TKIs (gefitinib or erlotinib).
Results: The BIM deletion polymorphism was present in 15.6% (32 
of 205) of patients. One patient was homozygous for the deletion, 
and the remaining 31 had heterozygous deletions. The majority of 
patients were younger than 65 years (74%), female (68%), never 
smokers (76%), and had stage IV NSCLC (67%). There were no 
associations between the BIM deletion polymorphism and clinico-
pathological features including gender, age, smoking status, histol-
ogy, stage, and number of metastasis sites. Patients with and without 
the BIM deletion polymorphism had similar objective response 
rates (91 vs. 84%, p = 0.585). Progression-free survival and over-
all survival did not differ significantly between patients with and 
without the BIM deletion polymorphism (median progression-free 
survival 12 vs. 11 months, p = 0.160; median overall survival 31 vs. 
30 months, p = 0.452). Multivariate analysis identified significantly 
predictive markers for clinical outcomes of EGFR TKIs including 
Eastern Cooperative Oncology Group performance status 0–1, ade-
nocarcinoma histology, recurrent disease, and EGFR mutation type. 
The results were validated in an independent cohort of 69 NSCLC 
patients.
Conclusions: It remains to be determined whether the BIM deletion 
polymorphism provides intrinsic resistance or decreased sensitivity 
to EGFR TKIs in EGFR-mutant NSCLC patients.
Key Words: Non–small-cell lung cancer, Epidermal growth factor 
receptor tyrosine kinase inhibitors, BIM deletion polymorphism.
(J Thorac Oncol. 2015;10: 903–909)
Non-small cell lung cancer (NSCLC) is a major cause of cancer-related death.1,2 Among patients with advanced 
NSCLC, cytotoxic chemotherapy has a response rate of 20% to 
35% and a median survival time of 10 to 12 months.3,4 Recent 
insights into the molecular mechanisms of NSCLC have led to 
the development of epidermal growth factor receptor (EGFR) 
tyrosine kinase inhibitors (TKIs), including gefinib, erlotinib, 
and afatinib. These EGFR TKIs are superior to chemotherapy 
as first-line treatments of EGFR-mutant NSCLC.5–10 However, 
20% to 30% of patients with EGFR-mutations do not respond 
to EGFR TKIs because of de novo or intrinsic resistance.11 
Although several possible mechanisms have been investigated 
in preclinical and retrospective studies, the factors that predict 
treatment response to EGFR TKIs remain elusive.12–14
The BIM (also known as BCL2L11) gene encodes a 
BH3-only protein that is a proapoptotic member of the BCL2 
family of proteins and is required for promoting cell death.15 
Prior studies have demonstrated that BIM is essential for 
EGFR TKIs-induced killing of NSCLC cells. Similarly, sup-
pressing BIM expression is sufficient to confer in vitro TKI 
resistance.16–19 Given these findings, it is important to describe 
the impact of the BIM deletion polymorphism on EGFR TKIs 
treatment in EGFR-mutant NSCLC patients. A recent study 
demonstrated that patients with the BIM deletion polymor-
phism had a lower median progression-free survival (PFS) 
than did those without the polymorphism (6.6 vs. 11.9 months; 
p = 0.003).20 However, the relationship between the BIM dele-
tion polymorphism and the efficacy of EGFR TKIs against 
EGFR-mutant NSCLC has not been completely elucidated. 
Therefore, the aim of this study was to determine whether the 
BIM deletion polymorphism influences the clinical outcomes 
of NSCLC with EGFR TKI treatment.
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MATERIALS AND METHODS
Study Populations
A total of 227 patients with EGFR-mutant NSCLC 
who received EGFR TKIs between July 2008 and April 2013 
were retrospectively reviewed from the lung cancer data-
base of Samsung Medical Center. Patients were excluded if 
they had insufficient archival tissue (n = 14) or EGFR exon 
20 mutations (n = 8: 4 patients with insertion and/or dele-
tion mutations, 2 with missense mutations, 2 with duplica-
tion mutations). Previous research has suggested that exon 
20 mutations are associated with poor treatment responses to 
EGFR TKIs.21,22 Therefore, the eight patients with EGFR exon 
20 mutations were excluded from this study.
Patients either received oral gefitinib (250 mg per day) 
or oral erlotinib (150 mg per day). Every two cycles, patients’ 
treatment responses were evaluated using a spiral computed 
tomography scan and the Response Evaluation Criteria in 
Solid Tumors version 1.1.23
The primary objective of this study was to analyze 
the effect of the BIM deletion polymorphism on the PFS of 
patients with EGFR-mutant NSCLC who were treated with 
EGFR TKIs. The secondary objectives included comparison 
of the following clinical features between patients with and 
without the BIM deletion polymorphism: (1) clinicopathologic 
distribution according to BIM status; (2) objective response 
rate (ORR) and disease control rate (DCR) for EGFR TKIs; 
and (3) overall survival (OS). This study was approved by 
the Institutional Review Board of Samsung Medical Center. 
Informed consent was waived because the study was based on 
retrospective administrative and clinical data.
Tissue Analysis and EGFR Mutation Testing
A pathologist reviewed the tumor contents and histo-
logic review of all of the samples. EGFR (exons 18–21) muta-
tions were analyzed by directional sequencing of polymerase 
chain reaction (PCR) fragments amplified with genomic DNA 
from formalin-fixed paraffin embedded (FFPE) tissue. Either 
standard methodology or the peptide nucleic acid-locked 
nucleic acid PCR clamp method was used.24,25
Genotyping of BIM Deletion Polymorphism
Because previous studies showed concordance between 
matched germline (peripheral blood) and somatic (fresh/fro-
zen tumor tissue) DNA, we used peripheral blood samples 
for genotyping of BIM deletion polymorphism.26,27 Genomic 
DNA was extracted from peripheral blood using the DNeasy 
Blood & Tissue Kit (Qiagen, Tokyo, Japan) according to the 
manufacturer’s protocol. PCR was carried out to detect the 
BIM deletion polymorphism. The primer sequence and cycling 
conditions have been previously described in detail.20 The 
PCR reactions were performed using the GoTaq Long PCR 
Master Mix (Promega, Madison, WI), and human genomic 
DNA included in the GoTaq Long PCR Master Mix kit was 
used as positive control. The PCR products (1323 base pair for 
deleted BIM and 4226 base pair for wild-type BIM) were ana-
lyzed on 1% agarose gels (Supplemental Fig. 1, Supplemental 
Digital Content 1, http://links.lww.com/JTO/A821).
Statistical Analysis
We calculated the PFS from the initiation of EGFR TKIs 
therapy until tumor progression or until death from any cause. 
OS was defined as the time from the initiation of EGFR TKIs 
therapy to death from any cause. Either the χ2 test or Fisher 
exact test was used to analyze the differences between the clin-
icopathologic characteristics of the BIM-deleted and wild-type 
populations. Kaplan–Meier methodology was used to estimate 
survival, which was expressed as a mean with a range and two-
sided 95% confidence interval (CI). Using Cox proportional 
hazard regression analyses, univariate and multivariate hazard 
ratios were generated for the following factors: age, gender, 
smoking history, performance status (Eastern Cooperative 
Oncology Group [ECOG]), pathology, stage, number of metas-
tasis, type of EGFR mutation, type of EGFR TKIs, and line 
of EGFR TKIs. Two-sided p values less than 0.05 were con-
sidered statistically significant. All analyses were performed 
using SPSS (version 19.0, SPSS Inc., Chicago, IL).
RESULTS
Prevalence and Clinicopathological 
Characteristics of the BIM Deletion Polymorphism
Table 1 summarizes the demographic and clinicopatho-
logic characteristics of the 205 patients. The median patient 
age was 59 years, and 68% were female. The majority of 
patients were never smokers (76%) and had ECOG perfor-
mance status (PS) of 0–1 (94%), tumor stage IV (67%) with 
adenocarcinoma (99%), and one or two metastatic sites (79%). 
Among 205 patients, 68 (33%) received EGFR TKIs as first-
line treatment. More patients were treated with gefitinib than 
with erlotinib (67% vs. 33%, respectively).
The exon 19 deletion was the most common mutation, 
accounting for 56% of mutations. The second most common 
was the L858R mutation (39%). Other EGFR mutations such 
as rare or complex mutations included exon 18 point muta-
tions (Gly 719 to Ser, Ala or Cys [G719S/A/C], n = 6 patients) 
and complex mutations (deletion and missense mutations in 
exon 19 or 21, n = 5; Table 1).
A total of 32 patients (15.6%) were found to have the BIM 
deletion polymorphism. The deletion was heterozygous in 31 
patients, and homozygous in 1 patient. The BIM deletion polymor-
phism had no association with basic clinicopathologic variables.
Response
By the end of data collection in June 2014, 22 patients 
(11%) were still receiving EGFR TKIs. The most common 
reasons for treatment discontinuation were disease progres-
sion (n = 171), drug toxicity (n = 6), and loss to follow-up 
(n = 5). Patients had similar ORRs regardless of their BIM 
deletion polymorphism status (91% [with mutation] vs. 84% 
[without], p = 0.585). Similarly, there was no difference 
between the DCR values of the two groups (94% [with muta-
tion] vs. 94% [without], p = 0.614; Table 1).
Survival
The median follow-up duration was 21.8 months (range 
0.5–91.2). In the total population, the median PFS and OS were 
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11.1 (95% CI: 9.8–12.4) and 30.3 months (95% CI: 25.4–35.3), 
respectively. The possible predictive factors of EGFR TKIs 
treatment efficacy were analyzed as subgroups in terms of PFS 
(Table 2). Univariate analysis revealed several factors that are 
significantly associated with poor PFS. These include male 
sex, former or current smoking, ECOG PS 2–4, squamous cell 
carcinoma, stage IV, and number of metastasis sites. There were 
similar PFS values regardless of BIM deletion polymorphism 
status (median PFS 11.9 [with mutation] vs. 10.9 (without) 
months, p = 0.160 [Fig. 1A]). Similarly, OS was comparable 
between the groups (median OS 31.2 [with mutation] vs. 30.3 
months [without], p = 0.452 [Fig. 1B]). Multivariate analysis 
revealed that ECOG PS 0–1, adenocarcinoma histology, recur-
rent disease, and EGFR mutation type were all significant 
predictive markers for clinical outcomes with EGFR TKI treat-
ment (Table 2 and Supplemental Table 1, Supplemental Digital 
Content 2, http://links.lww.com/JTO/A822).
Validation from Independent NSCLC Cohort
Because the results in this study were inconsistent with 
previous studies, we studied BIM deletion polymorphism using 
peripheral blood from an independent cohort of 69 NSCLC 
patients (Supplemental Table 2, Supplemental Digital Content 
2, http://links.lww.com/JTO/A822). The BIM deletion poly-
morphism was present in 14.5% (10 of 69) of patients. Two 
patients were homozygous for the deletion, and the remaining 
eight had heterozygous deletions. Patients with and without 
the BIM deletion polymorphism had similar ORRs (70.0% vs. 
74.6%, p = 0.713). PFS did not differ significantly between 
patients with and without the BIM deletion polymorphism 
(median PFS 11.6 vs. 9.7 months, p = 0.599; Supplemental 
Fig. 2, Supplemental Digital Content 3, http://links.lww.com/
JTO/A823). These results validated that the presence of the 
BIM deletion polymorphism was not associated with treat-
ment response to EGFR TKIs.
DISCUSSION
Recent data have demonstrated that the BIM deletion 
polymorphism, a germline mutation, is particularly influential 
in the targeted therapy-induced apoptosis of both blood and 
solid tumor cancers.28–30 In particular, this polymorphism is 
thought to be associated with intrinsic resistance to targeted 
therapies such as EGFR TKIs. Despite a large sample size, 
this study fails to demonstrate a correlation between BIM 
deletion polymorphism status and clinical outcomes in EGFR 
mutant NSCLC treated with EGFR TKIs.
It is noteworthy that the BIM deletion polymorphism is 
relatively common in East Asian populations but is absent in 
Africans and Europeans.20 In the current study, the BIM dele-
tion polymorphism was present in 32 of 205 patients (15.6%). 
One patient (0.5%) was homozygous for this deletion. These 
proportions are relatively consistent with prior reports.20,31–33 
We also found that the distribution of BIM deletion polymor-
phisms was not associated with any specific clinicopathologic 
features.
In the previous study by Ng et al.,20 patients with BIM 
deletion polymorphism had significantly shorter PFS than did 
patients without the polymorphism after EGFR TKIs (6.6 vs. 
11.9 months, respectively, p = 0.0027). Others have previ-
ously demonstrated the correlation between the BIM deletion 
polymorphism and poor treatment response rates (to EGFR 
TKIs) and short PFS in patients with EGFR-mutant NSCLC 
(Table 3).33–35 On the basis of these results, studies have high-







Deletion +   
(n = 32)
BIM 
deletion –  
(n = 173) P value
Basic clinicopathologic variables
  Age, mean ± SD 59 ± 10 59 ± 10 59 ± 10 0.898
  Age, n (%) 0.749
   <65 152 (74) 23 (72) 129 (75)
   ≥65 53 (26) 9 (28) 44 (25)
  Sex, n (%) 0.174
   Male 66 (32) 7 (22) 59 (34)
   Female 139 (68) 25 (78) 114 (66)
  Smoking history, n (%) 0.457
   Never 156 (76) 26 (81) 130 (75)
   Former/current 49 (24) 6 (19) 43 (25)
  ECOG PS, n (%) 0.697
   0–1 192 (94) 31 (97) 161 (93)
   2–4 13 (6) 1 (3) 12 (7)
  Pathology, n (%) 1.000
   Adenocarcinoma 203 (99) 32 (100) 171 (99)
   Squamous 2 (1) 0 2 (1)
  Stage, n (%) 0.060
   IIIB 8 (4) 0 8 (5)
   IV 138 (67) 19 (59) 119 (69)
   Postoperative relapse 59 (29) 13 (41) 46 (27)
  No. of metastasis, n (%) 0.951
   1–2 161 (79) 25 (78) 136 (79)
   ≥3 44 (21) 7 (22) 37 (21)
  EGFR mutation, n (%) 0.348
   Exon 19 deletion 114 (56) 20 (63) 94 (54)
   L858R mutation 80 (39) 11 (34) 69 (40)
   Othersa 11 (5) 1 (3) 10 (6)
  EGFR TKIs, n (%) 0.298
   Gefitinib 124 (61) 22 (69) 102 (59)
   Erlotinib 81 (39) 10 (31) 71 (41)
  Line of EGFR TKIs, n (%) 0.571
   First 68 (33) 12 (38) 56 (32)
   Second or more line 137 (67) 20 (62) 117 (68)
Treatment response
  Objective tumor response 175 (85) 29 (91) 146 (84) 0.585
  Disease control 193 (94) 30 (94) 163 (94) 1.000
aOthers mutation: Exon 18 point mutation (Gly 719 change to Ser, Ala or Cys 
[G719S/A/C]), six patients; complex mutation (deletion and missense mutation in exon 
19 or 21), seven patients.
ECOG PS, Eastern Cooperative Oncology Group performance status; EGFR, 
epidermal growth factor receptor, TKIs, tyrosine kinase inhibitors.
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deacetylase inhibitors in patients with the BIM deletion poly-
morphism.19,32 However, the BIM deletion polymorphism was 
not predictive of EGFR TKIs outcome in this study, which is 
consistent with previous findings in Korea from Lee et al.31 
Data from Lee et al.31 demonstrated no difference in the PFS 
among patients with and without the BIM deletion polymor-
phism (11.9 months with BIM deletion vs. 11.3 months with-
out, p = 0.791). Similarly, Isobe et al.32 reported that patients 
with the BIM deletion polymorphism had similar ORR and 
DCR but shorter PFS than did patients without the mutation.
Different BIM expression levels may explain the con-
tradictory findings regarding the deletion polymorphism and 
EGFR TKI outcomes. BIM upregulation, especially of the pro-
apoptotic isoform containing the BH3 domain, is required for 
TKIs to induce apoptosis. However, a deletion polymorphism 
in the BIM gene leads to alternatively spliced BIM isoforms that 
lack this crucial BH3 domain.18,36 Therefore, one hypothesis is 
that low BIM expression of the BH3 domain is associated with 
an unfavorable response to EGFR TKIs.34 The current study and 
a report by Lee et al.31 analyzed the BIM deletion polymorphism 
using genomic DNA extracted from peripheral blood and FFPE 
tissues. To establish the role of BIM as a predictor of treatment 
efficacy, it is useful to measure the BIM RNA levels in patients 
before treatment with EGFR TKIs.
TABLE 2.  Univariate and multivariate analysis for progression-free survival
Variable
Univariate Analysis Multivariate Analysis
Hazard Ratio P Value Hazard Ratio P Value
Age, n (%)
  <65 1.00
  ≥65 0.92 (0.65–1.29) 0.609
Sex, n (%)
  Female 1.00 1.00
  Male 1.55 (0.12–2.15) 0.008 1.37 (0.85–2.21) 0.193
Smoking history, n (%)
  Never 1.00 1.00
  Former/current 1.47 (1.03-2.12) 0.036 1.06 (0.62-1.82) 0.824
ECOG PS, n (%)
  0–1 1.00 1.00
  2–4 1.99 (1.12–3.53) 0.019 2.10 (1.18–3.75) 0.012
Pathology, n (%)
  Adenocarcinoma 1.00 1.00
  Squamous 5.06 (1.22–20.9) 0.025 4.50 (1.05–19.4) 0.043
Stage, n (%)
  Postoperative relapse 1.00 1.00
  IIIB 2.29 (1.07–4.92) 0.033 2.68 (1.24–5.81) 0.013
  IV 1.99 (1.39–2.83) 0.000 1.90 (1.32–2.74) 0.001
No. of metastasis, n (%)
  1–2 1.00 1.00
  ≥3 2.08 (1.46–2.96) 0.000 1.87 (1.29–2.71) 0.001
EGFR mutation, n (%)
  Exon 19 deletion 1.00 1.00
  L858R 0.94 (0.69–1.28) 0.688 0.98 (0.71–1.36) 0.921
  Othersa 1.81 (0.94–3.47) 0.076 2.23 (1.15–4.32) 0.018
EGFR TKI, n (%)
  Gefitinib 1.00
  Erlotinib 0.94 (0.69–1.28) 0.944
Line of EGFR TKI, n (%)
  First 1.00
  Second or more line 1.02 (0.74–1.41) 0.911
BIM polymorphism, n (%)
  Absent 1.00
  Present 0.74 (0.49–1.13) 0.162
aOthers mutation: Exon 18 point mutation (Gly 719 change to Ser, Ala or Cys [G719S/A/C]), six patients; complex mutation (deletion and missense mutation in exon 19 or 21), 
five patients.
ECOG PS, Eastern Cooperative Oncology Group performance status; EGFR, epidermal growth factor receptor; TKIs tyrosine kinase inhibitors.
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It is also worth noting that proapoptic BCL2 fam-
ily members such as BAX, BAK, and other BH3-only pro-
teins including BAD and PUMA might be key players in the 
apoptotic response in oncogene-addicted cancer. BAX and 
BAK are often referred to as effector proteins as they are 
required for activation of the apoptosis.37 Altered BAX and 
BAK expression is frequently reported in NSCLC.38–40 None 
of these studies conclude that altered BAX or BAK expres-
sion has significant value as a prognostic marker. Sun et al.41 
demonstrated that PUMA induction is correlated with EGFR-
TKI sensitivity and inhibition of the PI3K/AKT pathway. The 
crucial role the proapoptotic proteins BAX and BAK play in 
response to EGFR TKIs warrants further study.
Other concomitant genetic alterations beyond EGFR 
mutations could conceivably accelerate or delay cancer pro-
gression. For example, the T790M mutation, found in 50% to 
63% of patients, is well known to induce acquired resistance to 
EGFR TKIs.42,43 However, the impact of pretreatment T790M 
mutations on the sensitivity of EGFR TKIs remains contro-
versial.44–46 The incidence of pretreatment T790M mutations 
is highly dependent on the sensitivity of the detection method. 
Therefore, the true frequency associated with drug resistance 
remains unknown. We did not identify any patients harbor-
ing germline T790M mutations in the current study. However, 
coexistence of the T790M mutation before treatment may 
have been underappreciated in this report, because the peptide 
FIGURE 1.  Kaplan–Meier curves for progression-free survival (A) and overall survival (B) according to BIM status.
TABLE 3.  Results from Recent Studies of BIM for EGFR-Mutant NSCLC Treated With EGFR TKIs
Reference No. Method Specimen








Ng et al.19 141 DNA polymorphism Tumor tissue or peripheral blood 26 (18.4%) Not reported 6.6 vs. 11.9a Not reported
Faber et al.33 24 mRNA expression Tumor tissue 9 (37.5%)b 29% vs. 57%a 4.7 vs. 13.7a Not reported
Costa et al.34 50 mRNA expression Tumor tissue 26 (52.0%)c 32% vs. 88%a 7.2 vs. 12.9a 20.8 vs. 24.5
Zhao et al.32 166 DNA polymorphism Tumor tissue 16 (9.6%) 25% vs. 66%a 4.7 vs. 11.0a Not reported
Lee et al.30 197 DNA polymorphism Tumor tissue 21 (10.9%) Not reported 11.3 vs. 11.9 Not reported
Isobe et al.31 70 DNA polymorphism Tumor tissue or peripheral 13 (18.6%) 62% vs. 65% 7.6 vs. 17.8a 39.2 vs. 45.4
Current study 205 DNA polymorphism Blood, peripheral blood 32 (15.6%) 91% vs. 84% 11.9 vs. 10.9 31.2 vs. 30.3
ap < 0.05.
bLow BIM levels, defined as relative mRNA to β-actin less than 30.
cLow/intermediate BIM levels, defined as low (<1.83) or intermediate (1.83–2.96).
PFS, progression-free survival; EGFR, epidermal growth factor receptor; TKIs, tyrosine kinase inhibitors; OS, overall survival.
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nucleic acid clamp method (which is a more sensitive detec-
tor of EGFR mutations than of T790M mutations) was used. 
In the future, patients lacking sensitivity to EGFR TKIs will 
need to be worked-up further using additional genetic analy-
ses such as TP53,35,47 PTEN loss,48 and PIK3CA mutations.49 
There may be additional ethnic differences in BIM polymor-
phisms between Far East Asian and East Asian.
We validated the clinicopathologic features that were 
predictive of outcomes to EGFR TKIs. Patients with postoper-
ative relapse had significantly better prognoses than did those 
with stage IIIB/IV disease, which is consistent with previously 
reported findings.6 The more favorable prognosis in patients 
with relapse can be explained by the lower tumor burden in 
these patients compared with that in advanced metastatic dis-
ease (ρ correlation efficient 0.149, p = 0.033). In addition, the 
number of metastatic sites at baseline was significantly associ-
ated with poor survival.
The present study had several limitations. Because the 
study was retrospective in nature, there may have been unde-
fined bias regarding clinical outcomes. We analyzed the BIM 
deletion polymorphisms using genomic DNA from periph-
eral blood samples only. A report by Isobe et al.32 showed that 
there is no discordance between the BIM status of peripheral 
blood and FFPE samples; still, validating the BIM status in the 
tumor tissue would have been ideal. We did not analyze other 
coexisting genetic abnormalities beyond that of the BIM dele-
tion polymorphism. Therefore, the underlying complex biol-
ogy of EGFR-mutant NSCLC and tumor heterogeneity were 
not fully evaluated.
In this study, the presence of the BIM deletion poly-
morphism was not associated with treatment response to 
EGFR TKIs. Well-designed prospective studies are required 
to determine whether this polymorphism contributes to the 
heterogeneity of EGFR TKI responses among patients with 
EGFR-mutant NSCLC.
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